Drug Approval | December 28, 2021
Aurobindo to manufacture and market molnupiravir
The drug will be marketed under the brand name Molnaflu
The drug will be marketed under the brand name Molnaflu
The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The site's strategic location in the logistics hubs of the Auvergne Rhone-Alpes region is an advantage, along with the benefit of geographical proximity to Arrow's headquarters in Lyon
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Aurobindo has one of the most enduring generics ecosystems among peers
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
Subscribe To Our Newsletter & Stay Updated
